UPI | By HealthDay News
A new study with the cannabidiol-based Epidiolex reduced seizures in children with the rare form of epilepsy by roughly half.
There’s new data supporting the use of Epidiolex — the first cannabidiol CBD medicine approved by the U.S. Food and Drug Administration — to help curb a form of epilepsy.
The research found that the drug reduced seizures by nearly half in children with Dravet syndrome, a rare and severe form of the neurological disorder. The FDA approved Epidiolex last fall for the treatment of Dravet syndrome and another rare but severe form of childhood epilepsy, Lennox-Gastaut syndrome. The new study was funded by GW Research Ltd., developer of Epidiolex.